{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:21:19Z","timestamp":1792668079317,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.lungcan.2025.108496","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T15:53:44Z","timestamp":1742054024000},"page":"108496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-5587","authenticated-orcid":false,"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-7124","authenticated-orcid":false,"given":"Jong-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8230-5232","authenticated-orcid":false,"given":"Pongwut","family":"Danchaivijitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-597X","authenticated-orcid":false,"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baogang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4744-4533","authenticated-orcid":false,"given":"Adlinda","family":"Alip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8123-5965","authenticated-orcid":false,"given":"Hailin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-6477","authenticated-orcid":false,"given":"Soon Hin","family":"How","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-5138","authenticated-orcid":false,"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7724-0481","authenticated-orcid":false,"given":"Hiroshige","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali","family":"Nahit \u015eendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Gyoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-270X","authenticated-orcid":false,"given":"Patrapim","family":"Sunpaweravong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4193-841X","authenticated-orcid":false,"given":"Joshua M.","family":"Bauml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7262","authenticated-orcid":false,"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108496_b0005","unstructured":"World Health Organization. Global Cancer Observatory: Cancer Today. Asia. Accessed August 21, 2024. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/935-asia-fact-sheet.pdf."},{"key":"10.1016\/j.lungcan.2025.108496_b0010","unstructured":"World Health Organization. Global Cancer Observatory: Cancer Today. Eastern Asia. Accessed August 21, 2024. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/906-eastern-asia-fact-sheet.pdf."},{"key":"10.1016\/j.lungcan.2025.108496_b0015","unstructured":"American Cancer Society. Key statistics for lung cancer. Accessed July 1, 2024. https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html."},{"issue":"48","key":"10.1016\/j.lungcan.2025.108496_b0020","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108496_b0025","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res."},{"issue":"suppl 1","key":"10.1016\/j.lungcan.2025.108496_b0030","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene."},{"key":"10.1016\/j.lungcan.2025.108496_b0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct Target Ther."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108496_b0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108496_b0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med."},{"issue":"suppl 3","key":"10.1016\/j.lungcan.2025.108496_b0050","first-page":"1","article-title":"First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes","volume":"9","author":"Valdiviezo Lama","year":"2024","journal-title":"Ann Oncol."},{"key":"10.1016\/j.lungcan.2025.108496_b0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2021.10.020","article-title":"Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations","volume":"162","author":"Bazhenova","year":"2021","journal-title":"Lung Cancer."},{"issue":"4S","key":"10.1016\/j.lungcan.2025.108496_b0060","first-page":"S35","article-title":"Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: a real-world","volume":"18","author":"Girard","year":"2023","journal-title":"US Attrition Analysis. J Thorac Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108496_b0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40801-022-00302-w","article-title":"Retrospective analysis of real-world management of EGFR-mutated advanced NSCLC, after first-line EGFR-TKI treatment: US treatment patterns, attrition, and survival data","volume":"9","author":"Nieva","year":"2022","journal-title":"Drugs Real World Outcomes."},{"key":"10.1016\/j.lungcan.2025.108496_b0070","article-title":"EP08.02-082 Treatment patterns and outcomes of first-line osimertinib-treated advanced EGFR mutated NSCLC patients: a real-world study","volume":"17(9S):S440","author":"Lee","year":"2022","journal-title":"J Thorac Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108496_b0075","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer."},{"issue":"16 suppl","key":"10.1016\/j.lungcan.2025.108496_b0080","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1200\/JCO.2023.41.16_suppl.9074","article-title":"Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol."},{"issue":"suppl 8","key":"10.1016\/j.lungcan.2025.108496_b0085","article-title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann Oncol."},{"key":"10.1016\/j.lungcan.2025.108496_b0090","unstructured":"TAGRISSO\u00ae (osimertinib) tablets, for oral use [package insert], AstraZeneca Pharmaceuticals, Wilmington, DE, 2024."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108496_b0095","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108496_b0100","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor\u2013resistant lung tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108496_b0105","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108496_b0110","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR\u2013MET bispecific antibody, in diverse models of EGFR exon 20 insertion\u2013driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108496_b0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin Lung Cancer."},{"key":"10.1016\/j.lungcan.2025.108496_b0120","unstructured":"RYBREVANT (amivantamab-vmjw) injection, for intravenous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; Revised February 2025."},{"issue":"22","key":"10.1016\/j.lungcan.2025.108496_b0125","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108496_b0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2023","journal-title":"Ann Oncol."},{"issue":"suppl 4","key":"10.1016\/j.lungcan.2025.108496_b0135","doi-asserted-by":"crossref","first-page":"S1668","DOI":"10.1016\/j.annonc.2023.10.592","article-title":"Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann Oncol."},{"issue":"suppl 4","key":"10.1016\/j.lungcan.2025.108496_b0140","doi-asserted-by":"crossref","first-page":"S1661","DOI":"10.1016\/j.annonc.2023.10.583","article-title":"LBA11 Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: a MARIPOSA-2 subgroup analysis","volume":"34","author":"Shih","year":"2023","journal-title":"Ann Oncol."},{"key":"10.1016\/j.lungcan.2025.108496_b0145","unstructured":"Taiwan Food and Drug Administration. Assessment report. Accessed September 30, 2024."},{"key":"10.1016\/j.lungcan.2025.108496_b0150","unstructured":"Rybrevant (amivantamab) 350mg concentrate for solution for infusion [package insert]. Janssen-Cilag Ltd."},{"key":"10.1016\/j.lungcan.2025.108496_b0155","unstructured":"Pharmaceuticals and Medical Devices Agency. List of in vitro companion diagnostics or medical devices (CDx Products) approved in Japan. Accessed October 28, 2024. https:\/\/www.pmda.go.jp\/files\/000270358.pdf."},{"key":"10.1016\/j.lungcan.2025.108496_b0160","unstructured":"Rybrevant 350 mg concentrate for solution for infusion [product information]. Janssen Biologics B.V."},{"issue":"16","key":"10.1016\/j.lungcan.2025.108496_b0165","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108496_b0170","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jtho.2024.09.026","article-title":"OA02.03. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC: longer follow-up of the MARIPOSA study","volume":"19","author":"Gadgeel","year":"2024","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.lungcan.2025.108496_b0175","unstructured":"European Commission approves RYBREVANT\u00ae (amivantamab) in combination with LAZCLUZE\u00ae (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer [press release]. December 30, 2024."},{"issue":"suppl 2","key":"10.1016\/j.lungcan.2025.108496_b0180","doi-asserted-by":"crossref","first-page":"S1245","DOI":"10.1016\/j.annonc.2024.08.2297","article-title":"Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: an early analysis from the phase III MARIPOSA study","volume":"35","author":"Besse","year":"2024","journal-title":"Ann Oncol."},{"issue":"suppl 3","key":"10.1016\/j.lungcan.2025.108496_b0185","article-title":"5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: exploratory analyses from the MARIPOSA study","volume":"9","author":"Campelo","year":"2024","journal-title":"ESMO Open."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108496_b0190","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006072","article-title":"Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer","volume":"11","author":"Khorana","year":"2023","journal-title":"J Immunother Cancer."},{"issue":"14","key":"10.1016\/j.lungcan.2025.108496_b0195","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood."},{"issue":"30","key":"10.1016\/j.lungcan.2025.108496_b0200","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor\u2013mutated non\u2013small cell lung cancer: primary results from the phase III PALOMA-3 study","volume":"42","author":"Leighl","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.lungcan.2025.108496_b0205","doi-asserted-by":"crossref","unstructured":"S.M. Lim, J.L. Tan, J.M. Dias, et al., Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC): interim results from the phase 2 PALOMA-2 study, Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4, 2024; Chicago, IL.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8612"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225003885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225003885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:20:50Z","timestamp":1753993250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225003885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":41,"alternative-id":["S0169500225003885"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108496","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108496"}}